JUN and breast carcinoma: In contrast to lung adenocarcinoma cells or HER2+ breast cancer cells, we observed no evidence for a potential partnership role for c-Jun as the total levels of c-Jun and its phosphorylation (S63) were diminished in Dasatinib treated cells.